I recently joined The REIT Forum and if you are looking for more investment ideas like this one, get them exclusively at The REIT Forum with access to our subscriber only portfolios.Amrita runs a boutique family office fund in beautiful Vancouver, where she leads the investment strategy for the family fund. The fund's objective is to invest capital in sustainable, growth-driven companies that maximize shareholder equity by meeting their growth-oriented goals. In addition, she also started her own award-winn ...

I recently joined The REIT Forum and if you are looking for more investment ideas like this one, get them exclusively at The REIT Forum with access to our subscriber only portfolios.Amrita runs a boutique family office fund in beautiful Vancouver, where she leads the investment strategy for the family fund. The fund's objective is to invest capital in sustainable, growth-driven companies that maximize shareholder equity by meeting their growth-oriented goals. In addition, she also started her own award-winn ...

The company is having its best day of relative performance versus the S&P 500 in nearly a year ...

Core Viewpoint - Amgen Inc. is experiencing strong performance and positive analyst outlook despite facing some challenges, with a maintained "Buy" rating and an increased price target from Cowen & Co. [1][5] Financial Performance - Amgen's fourth-quarter performance in 2025 exceeded expectations for both revenue and earnings per share, supporting a positive outlook from analysts [2][5] - The stock price is currently $338.59, reflecting a 1.80% decrease or $6.20 drop, with a market capitalization of approximately $182.32 billion [4] Growth Prospects - Key products like Repatha and Uplizna are expected to drive future growth, offsetting losses from Prolia and Xgeva [2][5] - Despite regulatory uncertainties and pipeline attrition, Amgen's long-term prospects remain strong, bolstered by positive data from Repatha and progress with MariTide [3][5] Market Activity - The stock has fluctuated between $338.59 and $349.50 today, with a yearly high of $353.25 and a low of $261.43 [4]

Hasbro, Inc. (NASDAQ:HAS) traded higher on Wednesday as investors reacted to fresh analyst optimism and a new entertainment licensing deal.The toy and games company also unveiled a major studio collaboration.Roth Capital analyst Eric Handler reiterated a Buy rating on Hasbro stock. He raised his price forecast from $96 to $105 following improved franchise momentum.New Licensing DealThe collaboration centers on the Voltron brand. Hasbro will develop toys, action figures and roleplay products inspired by the ...

AT&T announced a telecom network, cloud and satellite partnership with Amazon. AST SpaceMobile and GlobalStar sold off on the news. ...

Neils ChristensenNeils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada. He has worked exclusively within the financial sector since 2007, when he started with the Canadian Economic Press. Neils can be contacted at: 1 866 925 4826 ext. 1526 nchristensen at kitco.com @Neils_cShareDisclaimer: The views expressed ...

Over the last two days, Novo Nordisk A/S (NYSE:NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.Novo Nordisk 2026 GuidanceNovo Nordisk expects sales growth for 2026, which excludes revenue of $4.2 billion from the reversal of 340B provisions, is expected to be -5% to -13% at CER.The company said that the sales outlook is impacted by lower realized prices, including impacts related to the "Most Favoured Nations" agreement in the U.S. and the patent expiry of the sem ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...